Home Rehabilitation for Pulmonary Hypertension
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether a home exercise program can help people with Pulmonary Arterial Hypertension (PAH) improve heart health and quality of life. Participants will either follow a special exercise routine at home or continue with their usual care. The researchers aim to determine if home exercise can make the heart work more efficiently during activities like walking. Individuals diagnosed with PAH, on stable medication, and with access to a smartphone or email might be suitable for this study. As an unphased trial, this study offers a unique opportunity to contribute to research that could enhance daily living for those with PAH.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it requires that you have been on stable vasodilator dosing for at least 30 days before starting the study, with no planned changes during the 12-week study period.
What prior data suggests that this home rehabilitation program is safe for patients with Pulmonary Arterial Hypertension?
A previous study found the home-based rehabilitation program for patients with Pulmonary Arterial Hypertension (PAH) to be safe and effective. The program improved patients' functional abilities without causing serious side effects. Research has shown that exercise training does not worsen the condition. Overall, this type of exercise is well-tolerated by patients and enhances their exercise capacity and quality of life.12345
Why are researchers excited about this trial?
Researchers are excited about the home rehabilitation approach for pulmonary hypertension because it offers a unique way to manage the condition outside of a clinical setting. Unlike traditional treatments that often rely on medications such as vasodilators and anticoagulants, this method focuses on empowering patients to actively participate in their own care through structured exercise programs. Home rehabilitation could potentially improve patients' quality of life by making it easier to adhere to treatment routines and by promoting physical activity tailored to their individual needs. This approach is particularly promising because it shifts part of the management from hospitals to the comfort of patients' homes, which can enhance accessibility and convenience.
What evidence suggests that home rehabilitation is effective for pulmonary hypertension?
Research has shown that rehabilitation exercises at home can benefit people with pulmonary arterial hypertension (PAH). In this trial, participants in the Exercise Intervention Group will engage in a home-based rehabilitation program. Studies have found that exercise training can enhance exercise capacity and quality of life for patients with pulmonary hypertension. For instance, a home-based program proved safe and effective, improving health measures related to daily activities. Another study demonstrated that exercise programs conducted at home were as effective as those in specialized centers. These findings suggest that home rehabilitation could help manage PAH by improving physical fitness and overall well-being.23678
Are You a Good Fit for This Trial?
This trial is for patients with Pulmonary Arterial Hypertension (PAH), a type of high blood pressure affecting the lungs. Participants should be able to perform physical activities as part of a home rehabilitation program aimed at reducing cardiac effort and improving quality of life.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo a home rehabilitation program aimed at decreasing cardiac effort and improving quality of life
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Home Rehabilitation
Home Rehabilitation is already approved in European Union, United States for the following indications:
- Pulmonary Arterial Hypertension (PAH)
- Improvement of Cardiac Effort
- Enhancement of Quality of Life
- Pulmonary Arterial Hypertension (PAH)
- Improvement of Cardiac Effort
- Enhancement of Quality of Life
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Rochester
Lead Sponsor
United Therapeutics
Industry Sponsor
Dr. Martine Rothblatt
United Therapeutics
Chief Executive Officer since 1996
PhD in Medical Ethics from the Royal London College of Medicine and Dentistry, JD and MBA from UCLA
Dr. Michael Benkowitz
United Therapeutics
Chief Medical Officer since 2023
MD from Harvard Medical School
Mayo Clinic
Collaborator
University of Vermont Medical Center
Collaborator